/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Michelino De Laurentiis

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"(IT)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

668

Papers

24.0K

Citations

73

h-index

240

i10-index

Michelino De Laurentiis is an academic researcher from Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale". The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 73, co-authored 568 publications.

ORCID: 0000-0001-9009-1572

Research Topics

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Breast Cancer Treatment Studies Cancer Genomics and Diagnostics

Papers by this author

works

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

2018 · Journal of Clinical Oncology · 1,086 citations

https://doi.org/10.1200/jco.2018.78.9909

Dennis J. Slamon Patrick Neven Stephen Chia Peter A. Fasching

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

2019 · New England Journal of Medicine · 821 citations

https://doi.org/10.1056/nejmoa1911149

Dennis J. Slamon Patrick Neven Stephen Chia Peter A. Fasching

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

2021 · Annals of Oncology · 702 citations

https://doi.org/10.1016/j.annonc.2021.05.801

David Miles Joseph Gligorov Fabrice André David Cameron

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 · Annals of Oncology · 608 citations

https://doi.org/10.1093/annonc/mdy518

Sylvia Adams Sherene Loi Deborah Toppmeyer David W. Cescon

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · The Lancet Oncology · 532 citations

https://doi.org/10.1016/s1470-2045(17)30376-5

José Baselga Seock‐Ah Im Hiroji Iwata Javier Cortés

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

2002 · PubMed · 475 citations

Giuseppe Di Lorenzo Giampaolo Tortora Francesco Paolo D’Armiento Gaetano De Rosa

Research topics

topics

Advanced Breast Cancer Therapies

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Breast Cancer Treatment Studies

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat